$599

Zealand Announces Additional Topline Dasiglucagon Results

Zealand has announced positive topline results from its Ph3 dasiglucagon immunogenicity study. Recall, in March 2018, the company reported results stating the trial met primary and secondary endpoints.

This content is for Read Less members only.
Register
Already a member? Log in here